Healthcare
Sonova Holding AG(SONVY)
Live Price
Offline$48.32
-1.59% today
Window Change
-8.57%
Window
May 29, 2026 β Jun 18, 2026
- Market Cap
- $10.21B
- Revenue Growth
- +6.6%
- EPS Growth
- -9.8%
- Dividend Yield
- 2.6%
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 15 bars Β· May 29, 2026 β Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Sonova Holding AG (SONVY) is a Healthcare stock with a market cap of $10.21B and listed on OTC. The stock last traded around $48.32 and down 8.6% across the available one-year price window (May 29, 2026 β Jun 18, 2026). Baseline metrics include revenue growth of +6.6%, EPS growth of -9.8%, a dividend yield of 2.6%. What stands out right now is revenue +6.6%, EPS -9.8%, free cash flow +5.0% with operating margin 18.2% and ROIC 12.6%. The dividend matters to the case here, with a current yield around 2.6%. Valuation is more restrained than many high-expectation growth names at P/E 19.6 and price/sales 2.7. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines SONVY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Near sector median
+6.6% vs +7.6% peer median
Operating Margin
Near sector median
+18.2% vs +19.4% peer median
P/E
Below sector median
19.6 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 18, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +6.6% and EPS is at -9.8%, with operating margin around 18.2%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 2.6%, which matters if the thesis depends on income as much as growth.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SONVY
β
Normalized return
SPY
β
S&P 500
Excess Return
β
Relative to SPY
SONVY Max Drawdown
-8.57%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SONVY and SPY.
Company Overview
Sonova Holding AG
Other OTC
Sonova Holding AG designs, develops, manufactures, and distributes hearing care solutions for adults and children. It operates through two segments, Hearing Instruments and Cochlear Implants segments. The company offers wireless communication products; rechargeable hearing aids; wireless headsets, speech enhanced hearables, audiophile headphones, microphones, and wireless transmission systems; and audiological care services. It also provides hearing instruments under the Phonak, Unitron, and Hansaton brand names; cochlear implants under the Advanced Bionics brand; consumer hearing products under the Sennheiser brand; and audiological care services under the AudioNova, Audium, Audition SantΓ©, Boots Hearingcare, Connect Hearing, Geers, Hansaton, Lapperre, Schoonenberg, and Triton brands. The company sells its products through independent distributors; and provides hearing care services through a network of approximately 3,600 stores and clinics. It operates in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company was formerly known as Phonak Holding AG and changed its name to Sonova Holding AG in August 2007. Sonova Holding AG was founded in 1947 and is headquartered in StΓ€fa, Switzerland.
- Leadership
- Eric Bernard
- IPO Date
- Apr 6, 2011
- Employees
- 18.3k
- Street Address
- Laubisrutistrasse 28
- Mailing
- StΓ€fa, 8712
- Region
- StΓ€fa, CH
- Reporting Currency
- USD
- Investor Line
- 41 58 928 33 33
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 19.6
- EV/EBITDA
- 13.0
- Price/Sales
- 2.7
- Price/Book
- 4.2
Growth
- Revenue
- +6.6%
- EPS
- -9.8%
- Free Cash Flow
- +5.0%
Profitability
- Gross Margin
- 70.5%
- Operating Margin
- 18.2%
- Net Margin
- 13.5%
- ROE
- 20.4%
- ROIC
- 12.6%
Balance Sheet
- Debt/Equity
- 0.76
- Current Ratio
- 1.24
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.